Tarsus Pharmaceuticals (TARS) Cost of Revenue (2021 - 2026)

Tarsus Pharmaceuticals' Cost of Revenue history runs 6 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 80.31% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $34.9 million (up 112.84% YoY), while the FY2025 annual figure was $30.7 million, up 139.23% from the prior year.
• Cost of Revenue was $9.4 million for Q1 2026 at Tarsus Pharmaceuticals, down from $10.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $10.9 million in Q4 2025 to a low of -$555000.0 in Q4 2022.
• Historically, Cost of Revenue has averaged $3.9 million across 5 years, with a median of $3.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue sank 2212.5% in 2022, then jumped 759.95% in 2024.
• A 5-year view of Cost of Revenue shows it stood at -$555000.0 in 2022, then surged by 319.1% to $1.2 million in 2023, then surged by 305.1% to $4.9 million in 2024, then soared by 121.82% to $10.9 million in 2025, then retreated by 14.01% to $9.4 million in 2026.
• The last three Cost of Revenue figures came in at $9.4 million (Q1 2026), $10.9 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.